BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11562757)

  • 1. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.
    Vonderheide RH; Butler MO; Liu JF; Battle TE; Hirano N; Gribben JG; Frank DA; Schultze JL; Nadler LM
    Int J Oncol; 2001 Oct; 19(4):791-8. PubMed ID: 11562757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
    Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
    Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals.
    Yellin MJ; Brett J; Baum D; Matsushima A; Szabolcs M; Stern D; Chess L
    J Exp Med; 1995 Dec; 182(6):1857-64. PubMed ID: 7500031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
    Jin Y; Fuller L; Ciancio G; Burke GW; Tzakis AG; Ricordi C; Miller J; Esquenzai V
    Hum Immunol; 2004 Feb; 65(2):93-103. PubMed ID: 14969764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
    Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
    Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.
    Chaperot L; Plumas J; Jacob MC; Bost F; Molens JP; Sotto JJ; Bensa JC
    Exp Hematol; 1999 Mar; 27(3):479-88. PubMed ID: 10089910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
    Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions.
    Somoza C; Lanier LL
    Res Immunol; 1995; 146(3):171-6. PubMed ID: 8525049
    [No Abstract]   [Full Text] [Related]  

  • 9. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration.
    Lang S; Whiteside TL; Lebeau A; Zeidler R; Mack B; Wollenberg B
    Arch Otolaryngol Head Neck Surg; 1999 Jan; 125(1):82-8. PubMed ID: 9932594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice.
    Holländer GA; Castigli E; Kulbacki R; Su M; Burakoff SJ; Gutierrez-Ramos JC; Geha RS
    Proc Natl Acad Sci U S A; 1996 May; 93(10):4994-8. PubMed ID: 8643517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD54/intercellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation.
    Poudrier J; Owens T
    J Exp Med; 1994 May; 179(5):1417-27. PubMed ID: 7513009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules.
    Van den Hove LE; Van Gool SW; Vandenberghe P; Bakkus M; Thielemans K; Boogaerts MA; Ceuppens JL
    Leukemia; 1997 Apr; 11(4):572-80. PubMed ID: 9096698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model.
    Van Gool SW; Vandenberghe P; de Boer M; Ceuppens JL
    Immunol Rev; 1996 Oct; 153():47-83. PubMed ID: 9010719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
    Cella M; Scheidegger D; Palmer-Lehmann K; Lane P; Lanzavecchia A; Alber G
    J Exp Med; 1996 Aug; 184(2):747-52. PubMed ID: 8760829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dendritic cells in T cell activation.
    Ni K; O'Neill HC
    Immunol Cell Biol; 1997 Jun; 75(3):223-30. PubMed ID: 9243286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human duodenal epithelial cells constitutively express molecular components of antigen presentation but not costimulatory molecules.
    Byrne B; Madrigal-Estebas L; McEvoy A; Carton J; Doherty DG; Whelan A; Feighery C; O'Donoghue DP; O'Farrelly C
    Hum Immunol; 2002 Nov; 63(11):977-86. PubMed ID: 12392850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
    Ranheim EA; Kipps TJ
    J Exp Med; 1993 Apr; 177(4):925-35. PubMed ID: 7681471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
    Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
    Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.